Aims: To describe personality traits and their changes in mild cognitive impairment (MCI) and control subjects. Methods: Sixty-three MCI and 90 control subjects were asked to describe their current personality traits by the Structured Interview for the Five-Factor Model (SIFFM). For each subject, a close relative retrospectively assessed these descriptions both as to the previous and current personality traits, using the Revised NEO Personality Inventory, Form R (NEO-PI-R). Results: Self-assessed MCI subjects reported significantly lower scores in the openness dimension than control subjects [F(1, 150) = 9.84, p = 0.002, ηp2 = 0.06]. In current observer ratings, MCI subjects had higher scores on neuroticism [F(1, 137) = 7.55, p = 0.007, ηp2 = 0.05] and lower ones on extraversion [F(1, 137) = 6.40, p = 0.013, ηp2 = 0.04], openness [F(1, 137) = 9.93, p = 0.002, ηp2 = 0.07], agreeableness [F(1, 137) = 10.18, p = 0.002, ηp2 = 0.07] and conscientiousness [F(1, 137) = 25.96, p < 0.001, ηp2 = 0.16]. Previous personality traits discriminated the groups as previous openness [odds ratio (OR) = 0.97, 95% confidence interval (CI) = 0.95-0.99, p = 0.014] and conscientiousness (OR = 0.96, 95% CI 0.94-0.98, p = 0.001) were negatively related to MCI group membership. In MCI subjects, conscientiousness [F(1, 137) = 19.20, p < 0.001, ηp2 = 0.12] and extraversion [F(1, 137) = 22.27, p < 0.001, ηp2 = 0.14] decreased between previous and current evaluations and neuroticism increased [F(1, 137) = 22.23, p < 0.001, ηp2 = 0.14], whereas no significant change was found in control subjects. Conclusions: MCI subjects undergo significant personality changes. Thus, personality assessment may aid the early detection of dementia.

Keywords:
Mild cognitive impairment, Personality, Healthy elderly, Five-Factor Model
1.
Kuzma E, Sattler C, Toro P, Schönknecht P, Schröder J: Premorbid personality traits and their course in mild cognitive impairment: results from a prospective population-based study in Germany. Dement Geriatr Cogn Disord 2011;32:171-177.
2.
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B: Mild cognitive impairment. Lancet 2006;367:1262-1270.
3.
Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Bäckman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, De Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, Van Duijn C, Visser P, Petersen RC: Mild cognitive impairment - beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med 2004;256:240-246.
4.
Clément F, Belleville S, Bélanger S, Chassé V: Personality and psychological health in persons with mild cognitive impairment. Can J Aging 2009;28:147-156.
5.
von Gunten A, Pocnet C, Rossier J: The impact of personality characteristics on the clinical expression in neurodegenerative disorder - a review. Brain Res Bull 2009;80:179-191.
6.
Montserrat Mendez R, Antonietti JP, Donati A, Rossier J, von Gunten A: Personality traits and behavioural and psychological symptoms in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2013;35:87-97.
7.
Digman JM: Personality structure: emergence of the five-factor model. Annu Rev Psychol 1990;41:417-440.
8.
Pocnet C, Rossier J, Antonietti J-P, von Gunten A: Personality changes in patients with beginning Alzheimer disease. Can J Psychiatry 2011;56:408-417.
9.
Balsis S, Carpenter BD, Storandt M: Personality change precedes clinical diagnosis of dementia of the Alzheimer type. J Gerontol B Psychol Sci Soc Sci 2005;60:P98-P101.
10.
Chatterjee A, Strauss ME, Smyth KA, Whitehouse PJ: Personality changes in Alzheimer's disease. Arch Neurol 1992;49:486-491.
11.
Dawson DV, Welsh-Bohmer KA, Siegler IC: Premorbid personality predicts level of rated personality change in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2000;14:11-19.
12.
Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA: Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry 2007;64:1204-1212.
13.
Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, Salmon E, Baron JC, De Cristofaro MT, Padovani A, Borroni B, Franceschi M, Bracco L, Pupi A: MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004;63:2332-2340.
14.
Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706.
15.
Panza F, Solfrizzi V, Colacicco AM, D'Introno A, Capurso C, Palasciano R, Todarello O, Capurso S, Pellicani V, Capurso A: Cerebrovascular disease in the elderly: lipoprotein metabolism and cognitive decline. Aging Clin Exp Res 2006;18:144-148.
16.
Petersen RC, Waring SC, Smith GE, Tangalos EG, Thibodeau SN: Predictive value of APOE genotyping in incipient Alzheimer's disease. Ann NY Acad Sci 1996;802:58-69.
17.
Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D: Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-758.
18.
Krishnan KR, Tupler LA, Ritchie JC Jr, McDonald WM, Knight DL, Nemeroff CB, Carroll BJ: Apolipoprotein E-epsilon 4 frequency in geriatric depression. Biol Psychiatry 1996;40:69-71.
19.
Monastero R, Mariani E, Camarda C, Ingegni T, Averna MR, Senin U, Camarda R, Mecocci P: Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease. Acta Psychiatr Scand 2006;113:59-63.
20.
Müller-Thomsen T, Arlt S, Ganzer S, Mann U, Mass R, Naber D, Beisiegel U: Depression in Alzheimer's disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men. Dement Geriatr Cogn Disord 2002;14:59-63.
21.
Ramachandran G, Marder K, Tang M, Schofield PW, Chun MR, Devanand DP, Stern Y, Mayeux R: A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease. Neurology 1996;47:256-259.
22.
Scarmeas N, Brandt J, Albert M, Devanand DP, Marder K, Bell K, Ciappa A, Tycko B, Stern Y: Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002;58:1182-1188.
23.
Zubenko GS, Henderson R, Stiffler SJ, Stabler S, Rosen J, Kaplan BB: Association of the APOE epsilon 4 allele with clinical subtypes of late life depression. Biol Psychiatry 1996;40:1008-1016.
24.
Gabryelewicz T, Religa D, Styczynska M, Peplonska B, Pfeffer A, Wasiak B, Luczywek E, Golebiowski M, Androsiuk W, Czyzewski K, Przekop I, Barcikowska M: Behavioural pathology in Alzheimer's disease with special reference to apolipoprotein E genotype. Dement Geriatr Cogn Disord 2002;14:208-212.
25.
Heidrich A, Thome J, Rösler M, Baumer A: Apolipoprotein E-epsilon 4 allele frequency in late-onset depression. Biol Psychiatry 1997;41:912-914.
26.
Carr DB, Gray S, Baty J, Morris JC: The value of informant versus individual's complaints of memory impairment in early dementia. Neurology 2000;55:1724-1726.
27.
Morris JC: The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
28.
Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
29.
Van der Linden M, Adam S, Agniel A, Baisset-Mouly C, Bardet F, Coyette F, Desgranges B, Deweer B, Ergis A-M, Gély-Nargeot M-C, Grimonprez L, Juillerat A-C, Kalafat M, Pointrenaud J, Sellal F, Thomas-Antérion C: L'évaluation des troubles de la mémoire. Présentation de quatre tests de mémoire épisodique (avec leur étalonnage). Marseille, Solal, 2004.
30.
Godefroy O, Azouvi P, Robert P, Roussel M, LeGall D, Meulemans T: Dysexecutive syndrome: diagnostic criteria and validation study. Ann Neurol 2010;68:855-864.
31.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
32.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
33.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The neuropsychiatric inventory. Neurology 1994;44:2308-2314.
34.
Katz IR: Diagnosis and treatment of depression in patients with Alzheimer's disease and other dementias. J Clin Psychiatry 1998;59:38-44.
35.
Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
36.
Jorm AF, Jacomb PA: The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med 1989;19:1015-1022.
37.
Costa PT, McCrea RR: Revised Neo Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI): Professional Manual. Odessa, Psychological Assessment Resources, 1992.
38.
Rossier J, Meyer de Stadelhofen F, Berthoud S: The hierarchical structures of the NEO PI-R and the 16 PF 5. Eur J Psychol Assess 2004;20:27-38.
39.
Trull TJ: Structured Interview for the Five-Factor Model of Personality (SIFFM): Professional Manual. Odessa, Psychological Assessment Resources, 1997.
40.
Rolland J-P, Wayne D, Stumpf H: A psychometric examination of the French translations of the NEO-PI-R and NEO-FFI. J Pers Assess 1998;71:269-291.
41.
Plaisant O, Courtois R, Réveillère C, Mendelsohn GA, John OP: Factor structure and internal reliability of the French Big Five Inventory (BFI-Fr). Convergent and discriminant validation with the NEO-PI-R. Ann Med Psychol 2010;168:97-106.
42.
Plaisant O, Guertault J, Courtois R, Réveillère C, Mendelsohn GA, John OP: Big Five History: OCEAN of personality factors. Introduction of the French Big Five Inventory or BFI-Fr (in French). Ann Med Psychol 2010;168:481-486.
43.
Donati A, Pocnet C, Rossier J, von Gunten A: The impact of personality characteristics on the clinical expression of MCI (in French). Rev Med Suisse 2010;244:759-761.
44.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
45.
Ware CJG, Fairburn CG, Hope RA: A community-based study of aggressive behaviour in dementia. Int J Geriatr Psychiatry 1990;5:337-342.
46.
Smith-Gamble V, Baiyewu O, Perkins AJ, Gureje O, Hall KS, Ogunniyi A, Hui SL, Hendrie HC: Informant reports of changes in personality predict dementia in a population-based study of elderly African Americans and Yoruba. Am J Geriatr Psychiatry 2002;10:724-732.
47.
Talassi E, Cipriani G, Bianchetti A, Trabucchi M: Personality changes in Alzheimer's disease. Aging Ment Health 2007;11:526-531.
48.
Siegler IC, Welsh KA, Dawson DV, Fillenbaum GG, Earl NL, Kaplan EB, Clark CM: Ratings of personality change in patients being evaluated for memory disorders. Alzheimer Dis Assoc Disord 1991;5:240-250.
49.
Ausén B, Edman G, Almkvist O, Bogdanovic N: Personality features in subjective cognitive impairment and mild cognitive impairment - early indicators of dementia. Dement Geriatr Cogn Disord 2009;28:528-535.
50.
Terracciano A, McCrae RR, Brant LJ, Costa PT: Hierarchical linear modeling analyses of the NEO-PI-R scales in the Baltimore Longitudinal Study of Aging. Psychol Aging 2005;20:493-506.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.